[go: up one dir, main page]

WO2008004067A3 - Alpha-2-delta-1 selective compounds for disorders of the nervous system - Google Patents

Alpha-2-delta-1 selective compounds for disorders of the nervous system Download PDF

Info

Publication number
WO2008004067A3
WO2008004067A3 PCT/IB2007/001789 IB2007001789W WO2008004067A3 WO 2008004067 A3 WO2008004067 A3 WO 2008004067A3 IB 2007001789 W IB2007001789 W IB 2007001789W WO 2008004067 A3 WO2008004067 A3 WO 2008004067A3
Authority
WO
WIPO (PCT)
Prior art keywords
delta
alpha
disorders
nervous system
selective compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001789
Other languages
French (fr)
Other versions
WO2008004067A2 (en
Inventor
Zheng Li
Jacob Bradley Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2008004067A2 publication Critical patent/WO2008004067A2/en
Anticipated expiration legal-status Critical
Publication of WO2008004067A3 publication Critical patent/WO2008004067A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is directed to a method of treating a disorder or condition using an alpha-2-delta ligand with high affinity and selectivity for the alpha-2-delta-1 calcium channel subunit subtype. Administration of the alρha-2-delta-1 selective ligand, or a pharmaceutically acceptable salt, to a mammal, including a human, avoids or reduces the adverse effects compared to the administration of an alpha-2-delta non-selective ligand.
PCT/IB2007/001789 2006-06-30 2007-06-29 Alpha-2-delta-1 selective compounds for disorders of the nervous system Ceased WO2008004067A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81815406P 2006-06-30 2006-06-30
US60/818,154 2006-06-30

Publications (2)

Publication Number Publication Date
WO2008004067A2 WO2008004067A2 (en) 2008-01-10
WO2008004067A3 true WO2008004067A3 (en) 2009-01-29

Family

ID=38739992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001789 Ceased WO2008004067A2 (en) 2006-06-30 2007-06-29 Alpha-2-delta-1 selective compounds for disorders of the nervous system

Country Status (4)

Country Link
JP (1) JP2008013555A (en)
AR (1) AR061728A1 (en)
TW (1) TW200819123A (en)
WO (1) WO2008004067A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2211630E (en) 2007-11-05 2012-10-31 Unilever Nv Process for manufacturing tea products
JP7320494B2 (en) * 2017-05-26 2023-08-03 ノバッセイ エスエー Voltage-gated calcium channel auxiliary subunit α2δ and its uses
US20220296548A1 (en) * 2019-10-25 2022-09-22 Kyoto University Preventative or therapeutic agent for tauopathy

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021824A1 (en) * 1997-10-27 1999-05-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
WO1999031075A1 (en) * 1997-12-16 1999-06-24 Warner-Lambert Company 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO2000076958A2 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Mono- and disubstituted 3-propyl gamma-aminobutyric acids
WO2001028978A1 (en) * 1999-10-20 2001-04-26 Warner-Lambert Company Bicyclic amino acids as pharmaceutical agents
WO2002085839A1 (en) * 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
WO2003082807A2 (en) * 2002-03-28 2003-10-09 Warner-Lambert Company Llc Amino acids with affinity for the alpha-2-delta-protein
WO2004039367A1 (en) * 2002-10-31 2004-05-13 Pfizer Limited Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
WO2005030700A2 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Amino acids with affinity for the alpha2delta-protein
WO2005102390A2 (en) * 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
WO2006017293A2 (en) * 2004-07-13 2006-02-16 Regents Of The University Of California Models and methods for nociception, pain transduction, and screening for analgesic compounds
WO2006100606A2 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Preparation of beta-amino acid precursors via indium (iii) mediated markovnikov addition and knoevenagel condensation

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021824A1 (en) * 1997-10-27 1999-05-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
WO1999031075A1 (en) * 1997-12-16 1999-06-24 Warner-Lambert Company 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO2000076958A2 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Mono- and disubstituted 3-propyl gamma-aminobutyric acids
WO2001028978A1 (en) * 1999-10-20 2001-04-26 Warner-Lambert Company Bicyclic amino acids as pharmaceutical agents
WO2002085839A1 (en) * 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
WO2003082807A2 (en) * 2002-03-28 2003-10-09 Warner-Lambert Company Llc Amino acids with affinity for the alpha-2-delta-protein
WO2004039367A1 (en) * 2002-10-31 2004-05-13 Pfizer Limited Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
WO2005030700A2 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Amino acids with affinity for the alpha2delta-protein
WO2005102390A2 (en) * 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
WO2006017293A2 (en) * 2004-07-13 2006-02-16 Regents Of The University Of California Models and methods for nociception, pain transduction, and screening for analgesic compounds
WO2006100606A2 (en) * 2005-03-24 2006-09-28 Warner-Lambert Company Llc Preparation of beta-amino acid precursors via indium (iii) mediated markovnikov addition and knoevenagel condensation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIAN ET AL: "Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: An ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1075, no. 1, 23 February 2006 (2006-02-23), pages 68 - 80, XP005335558, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
JP2008013555A (en) 2008-01-24
AR061728A1 (en) 2008-09-17
TW200819123A (en) 2008-05-01
WO2008004067A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2007087431A3 (en) Sublingual fentanyl spray
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2009017837A3 (en) Sublingual fentanyl spray
WO2008030367A3 (en) Selective myostatin inhibitors
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2003049675A3 (en) Treating muscle wasting with selective androgen receptor modulators
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2008002490A3 (en) Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008089008A3 (en) Tetrahydrobiopterin prodrugs
WO2003096983A3 (en) Method of treating dyslipidemic disorders
WO2007112345A8 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2007095631A3 (en) New drug delivery system for crossing the blood brain barrier
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008052139A3 (en) Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
WO2009155139A9 (en) Use of isoindoles for the treatment of neurobehavioral disorders
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2007109288A3 (en) Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2008004067A3 (en) Alpha-2-delta-1 selective compounds for disorders of the nervous system
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007107442A3 (en) Bis1,2,3,4-tetrahydroisoquinoline derivatives and their uses as pharmaceuticals
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789463

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07789463

Country of ref document: EP

Kind code of ref document: A2